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Abstract
Inﬂuenza vaccination is recommended for cancer patients; however, adherence is low. We aimed to identify predictive factors for vaccination
among cancer patients. We conducted a case–control analysis of a patient cohort in the 2010–2011 inﬂuenza season. We included adult cancer
patients with solid malignancies undergoing chemotherapy, and haematological patients with active disease. Patients who died between
October and November 2010 (N = 43) were excluded from analysis. Cases received the 2011 seasonal inﬂuenza vaccine, and controls did not.
Data were obtained from patients’ records, and validated through personal interviews. We collected socio-demographic information, and data
on the malignancy and co-morbidities and triggers for vaccination and non-vaccination. We performed bivariate and multivariable analyses, in
which vaccination status was the dependent variable. Of 806 patients included in analysis, 387 (48%) were vaccinated. Variables associated with
vaccination on bivariate analysis were older age, higher socio-economic status, lower crowding index, marital status (widowed > mar-
ried > single), malignancy type (haematological > solid tumours) and time from diagnosis, low-risk malignancy, diabetes, past vaccination,
country of birth (non-Russian origin), and physicians’ recommendations. Predictive factors found to be independently associated with
vaccination on multivariable analysis were past vaccinations, low-risk malignancy, and country of birth. In the analysis conducted among
interviewees (N = 561), recommendations from the oncologist (OR 10.7, 95% CI 5.4–21.2) and from the primary-care physician (OR 3.35,
95% CI 2.05–5.49) were strong predictors for vaccination. We conclude that ‘habitual vaccinees’ continue inﬂuenza vaccinations when ill with
cancer. Physicians’ recommendations, especially the oncologist’s, have a major inﬂuence on patients’ compliance with inﬂuenza vaccination.
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Introduction
Annual vaccination against inﬂuenza is the most effective way
to avoid inﬂuenza and related complications [1]. Vaccination of
immunosuppressed patients, including cancer patients, is
universally recommended [2–6]. Among patients with cancer
admitted to hospital with respiratory symptoms during
inﬂuenza epidemics, 21–33% test positive for inﬂuenza, and
fatality rates in those with conﬁrmed inﬂuenza range between
11% and 33% [7]. However, inﬂuenza vaccination rates among
cancer patients are low [7,8].
The most common predictors for vaccination in the general
population are older age and the presence of chronic diseases
[9]. Other determinants include inﬂuenza vaccination in the
past, free-of-charge vaccination, higher education, and recom-
mendations from physicians, family, or friends [9]. The most
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common reasons for non-vaccination in the population are
misconceptions concerning vaccine safety, lack of faith in
vaccine efﬁcacy, and the absence of recommendations for
vaccination from healthcare providers [9].
Clinical data on inﬂuenza among cancer patients are scarce
and mostly based on small studies [7,10–12]. Current inﬂuenza
vaccination guidelines for cancer patients are not based on
actual evidence, and are thus less likely to be followed. Studies
assessing compliance with inﬂuenza vaccination and factors
that inﬂuence the acceptance or non-acceptance of the vaccine
in oncology patients are lacking. We have previously shown
that inﬂuenza vaccination is associated independently with
lower all-cause mortality in cancer patients [13]. In the current
study, we aimed to identify factors associated with inﬂuenza
vaccination, considering factors that cannot be modiﬁed, and
modiﬁable factors that can be targeted for future interven-
tions.
Materials and Methods
Study design and settings
This study was a case–control analysis of cohort members.
The study was conducted in the 2010–2011 inﬂuenza season
(October 2010 to April 2011) at Davidoff Centre, Rabin
Medical Centre, a primary-care and tertiary-care univer-
sity-afﬁliated hospital comprising oncology, haemato-oncology
and bone marrow transplantation wards. The hospital belongs
to the largest health maintenance organization (HMO) in
Israel, which insures 52.3% of its population [14]. We obtained
local research ethics committee approval for the study,
requesting oral informed consent for telephone/personal
interviews.
Participants
Cases were deﬁned as all cohort patients who received the
2011 seasonal trivalent inactivated inﬂuenza vaccine (‘vacci-
nated’). Controls were cohort patients who did not receive a
seasonal inﬂuenza vaccine (‘unvaccinated’). Administration and
receipt of the vaccine were according to physicians’ and
patients’ decisions. Data on seasonal inﬂuenza vaccination
were fully recorded in patients’ electronic health records. No
matching procedure was performed to allow the study of all
potential factors. The cohort included adult cancer patients
(>18 years of age) with solid and haematological malignancies
treated with chemotherapy, and patients who had received
autologous (up to 6 months after transplantation) or alloge-
neic (at any time) haematopoietic stem cell transplantation and
who were alive on December 2010 (thus having had the
opportunity to be vaccinated). We excluded patients with
untreated solid malignancies, haemato-oncological patients at
least 1 year in remission post-therapy, and patients insured
through other HMOs [13]. The viral strains included in this
season were A/Perth/16/2009 (H3N2), A/California/7/2009
(H1N1), and B/Brisbane/60/2008.
Variables and data sources
We collected a range of variables that might affect patients’
decisions on whether to be vaccinated. These included
socio-demographic factors, and information on the oncological
disease and comorbidities. Owing to the complexity of risk
classiﬁcation of different cancers, we deﬁned two broad
categories: high-risk malignancy, which included metastatic
solid tumours, leukaemia, including myelodysplastic syn-
dromes, and all haematopoietic stem cell transplantation
recipients; and low-risk malignancy, which included non-met-
astatic solid cancer, lymphoma, and multiple myeloma. Data
were collected from hard copy and electronic medical records,
including inpatient and outpatient records. Information on
recommendations for vaccination, reasons for vaccination and
non-vaccination, attitudes towards vaccination, vaccine-related
adverse events and a few socio-economic factors was obtained
through telephone or personal interviews conducted during
May–June 2011. The questionnaire had previously been
assessed for content validity in a pilot study among a small
group of lay volunteers, to ensure clarity and understandability,
and revised where necessary. We validated exposure to
vaccination reported in interviews by crossing it with data
from electronic sources.
Study size
The ﬁnal sample size provided a power of >70% to detect a
statistically signiﬁcant OR of >1.45 for inﬂuenza vaccination
(a = 0.05).
Statistical methods
We conducted a bivariate analysis to compare factors
predicting vaccination between vaccinated and unvaccinated
patients. Dichotomous data were compared by use of a
chi-square test or Fisher exact test, and continuous data by use
of the t-test or the Mann–Whitney U-test, as appropriate. We
carried out a multivariable analysis with vaccination as the
dependent variable. The covariates included factors associated
with vaccination that resulted in a statistically signiﬁcant
association (p < 0.05) in the bivariate analysis. We excluded
variables that were clinically related to each other and
signiﬁcantly correlated. Variables were entered into the
logistic regression model by forward stepwise inclusion.
Goodness-of-ﬁt was measured with Hosmer and Lemeshow
and –2 log-likelihood tests, and the predictive ability of the
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model was evaluated from the area under the receiver
operating characteristic (ROC) curve. ORs with 95% CIs are
reported. Data were analysed with SPSS version 20.0.
Results
Participants
We included 806 cancer patients who were actively treated
during the period of routine inﬂuenza vaccination (October–
November), of whom 387 (48%) were vaccinated. At the time
of vaccination, one of 363 (0.3%) were neutropenic (<500/lL)
and 65 of 363 (17.9%) were lymphopenic (<900/lL). The kappa
statistic for vaccination status between records and
self-reporting was 0.87 (standard error of 0.0021,
p < 0.001). Interviews were conducted with 561 patients.
The most common reason for not performing an interview
was patient death (Fig. 1).
Factors associated with vaccination on bivariate analysis
Vaccinated patients were older than unvaccinated patients
(66  13 vs. 60  15 years). Marital status was associated
with vaccination, and a signiﬁcantly lower percentage of
patients born in Russia was observed among vaccinated (32/
387, 8.3%) than among unvaccinated (62/419, 14.8%) patients.
A crowding index of >1 person/room was associated with
non-vaccination (68/269 (25.2%) vs. 91/246 (37%), respec-
tively). The percentage of patients in lower socio-economic
clusters [15] was also higher among unvaccinated patients (35/
383 (9.1%) vs. 67/418 (16%), respectively). There were no
signiﬁcant associations between vaccination and sex, ethnicity,
or years of education (Table 1).
There was no association between vaccination and Eastern
Cooperative Oncology Group performance status, body mass
index, smoking and hospitalization in the previous year. No
association was found with the Charlson comorbidity index or
speciﬁc comorbidities, with the exception of diabetes (97/387
(25.1%) among vaccinated patients vs. 81/419 (19.3%) among
unvaccinated patients, p 0.05). Vaccinated patients more
frequently received an inﬂuenza vaccine in the 10 years prior
to the studied winter (300/387 (77.5%) among vaccinated
patients vs. 136/419 (32.5%) among unvaccinated patients;
bivariate OR 7.1, 95% CI 5.2–9.8), more frequently received
the seasonal inﬂuenza vaccine in 2009 (258/387 (66.7%) vs. 85/
419 (20.3%); OR 7.9, 95% CI 5.7–10.8), more frequently
received the H1N1 vaccine in 2009 (124/387 (32%) vs. 35/
419 (8.4%); OR 5.2, 95% CI 3.4–7.8), and were more fre-
quently vaccinated against Streptococcus pneumoniae in the past
(260/387 (67.2%) vs. 117/419 (27.9%); OR 5.3, 95% CI 3.9–
7.1).
The type of cancer was signiﬁcantly associated with
vaccination status; a higher percentage of haematological
cancer patients and a lower percentage of breast cancer
patients were found among vaccinated patients (Table 2).
Differences with regard to radiation therapy probably
reﬂected the cancer type distribution. A longer time since
cancer diagnosis was associated with vaccination. High-risk
malignancy was inversely associated with vaccination. There
was no association between vaccination and steroid treatment,
active chemotherapy and documented neutropenia or lymp-
hopenia at the time of vaccine administration or during the
winter.
Among 561 interviewed patients, a signiﬁcant association
was found between vaccination and recommendations
FIG. 1. Patients’ ﬂow chart and reasons for exclusion from the preliminary cohort.
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to receive the vaccine from the treating oncologist or
primary-care physician (Table 3). Of vaccinated patients,
33.8% (99/293) reported that their oncologist recommended
inﬂuenza vaccination, as compared with only 5.2% (14/268) of
unvaccinated patients. Of vaccinated patients, 0.3% (1/293)
perceived that their oncologist actively recommended against
vaccination, as compared with 5.6% (15/268) of unvaccinated
patients. Similar results were obtained for the recommenda-
tions of the primary-care physician (Table 3). Compliance with
oncologists’ recommendations for vaccination was higher than
compliance with the primary physicians’ recommendations:
87.8% (99/113) of patients reporting that their oncologist
recommended vaccination were vaccinated, as compared with
67.3% (136/202) of patients reporting having received a
recommendation from their primary-care physician (p 0.001).
A ‘regular habit’ and a healthcare provider recommendation
were more frequently stated as reasons for than as reasons
against vaccination. The minority of triggers for or against
vaccination were accessibility issues (e.g. comfortable access to
clinics; shortage of vaccines). Of the vaccinated interviewees,
95 of 293 (32.4%) reported ‘avoiding inﬂuenza morbidity’ as
the trigger to be vaccinated. Of the unvaccinated interviewees,
63 of 268 (23.5%) reported concerns about side effects as a
reason not to be vaccinated.
Factors associated with vaccination on multivariable analysis
We used two multivariable models for factors independently
associated with vaccination: the ﬁrst for the entire cohort
(N = 806), and the second for patients who were interviewed
(n = 561) (Table 4). In the ﬁrst model, variables independently
associated with vaccination were non-Russian origin, number
of inﬂuenza vaccines in the last 5 years, H1N1 vaccine in the
2009–2010 inﬂuenza season, past pneumococcal vaccination,
and high-risk malignancy. Marital status, diabetes, inﬂuenza
vaccine in the past 10 years, type of cancer, radiation therapy
and time since diagnosis of cancer were available in the model,
but were not included in the ﬁnal model. The area under the
ROC curve for the model was 0.82 (95% CI 0.80–0.85). The
association between vaccination and the identiﬁed indepen-
dent factors remained similar in stratiﬁed analysis of three
Variable
Vaccinated
(N = 387) (%)
Unvaccinated
(N = 419) (%) p
Demographic and socio-economic characteristics
Age (years), mean  SD 66  13 60  15 <0.001
Sex (female) 213 (55) 251 (59.9) 0.163
Ethnicity No. evaluated = 387 No. evaluated = 418 0.279
Arab 19 (4.9) 28 (6.7)
Jew 368 (95.1) 390 (93.3)
Country of birth
Russia 32 (8.3) 62 (14.8) 0.004
Othera 355 (91.7) 357 (85.2)
Socio-economic clusterb No. evaluated = 383 No. evaluated = 418 0.003
1–4 35 (9.1) 67 (16)
5–10 348 (90.9) 351 (84)
Crowding-index (persons per room) No. evaluated = 269 No. evaluated = 246 0.004
≥1 68 (25.2) 91 (37)
<1 201 (74.8) 155 (63)
Years of education
≤12 213 (55) 219 (52.3) 0.127
>12 103 (26.6) 99 (23.6)
Unknown 1 (18.3) 101 (24.1)
Marital status
Married 290 (74.9) 307 (73.3) 0.012
Single/divorced/separated 41 (10.6) 70 (16.7)
Widowed 56 (14.5) 42 (10)
ECOG grade No. evaluated = 353 No. evaluated = 394 0.081
0–1 323 (91.5) 345 (87.6)
2–4 30 (8.5) 49 (12.4)
Medical background and comorbidities
BMI, mean  SD 26.20  4.55 26.55  5.31 0.314
Charlson Index, mean  SD 4.65  2.37 4.74  2.28 0.597
Congestive heart failure 38 (9.8) 28 (6.7) 0.105
Chronic pulmonary disease 22 (5.7) 21 (5) 0.671
Diabetes 97 (25.1) 81 (19.3) 0.05
Smoking 120 (31) 128 (30.5) 0.89
Hospitalization in the previous year 265 (68.5) 297 (70.9) 0.457
Past vaccinations
No. of inﬂuenza vaccines in the past 5 years,
median (range)c
3 (0–5) 0 (0–5) <0.001
Past inﬂuenza vaccine (in the last 10 years) 300 (77.5) 136 (32.5) <0.001
Inﬂuenza vaccine last year 258 (66.7) 85 (20.3) <0.001
H1N1 vaccine 2009–2010 124 (32) 35 (8.4) <0.001
Past pneumococcal vaccine 260 (67.2) 117 (27.9) <0.001
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
aComparison with patients born in Israel (N = 339), eastern Europe (N = 137), North Africa and elsewhere (N = 236).
No differences were observed among patients included in the ‘other category’.
bSocio-economic cluster according to the Israeli Central Bureau of Statistics clustering [15].
cMann–Whitney U-test.
TABLE 1. Demographics and back-
ground conditions
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patient subgroups (solid cancer without metastases, metastatic
solid cancers, and haematological patients).
In the second model, vaccination history remained signiﬁ-
cantly associated with vaccination, and the recommendations
of the oncologist (OR 10.7, 95% CI 5.4–21.2) and of the
primary-care physician (OR 3.35, 95% CI 2.05–5.49) were
strong predictors for vaccination. The crowding index was
not included in the ﬁnal model. The area under the ROC curve
for this model was 0.88 (95% CI 0.85–0.91).
Discussion
We assembled a cohort of actively treated oncological patients
during the winter of 2010–2011 to analyse factors associated
with inﬂuenza vaccination, both modiﬁable and non-modiﬁable.
The vaccination rates in our cohort were 46% (394/849)
among all patients and 48% (387/806) among patients alive on 1
December 2010. Reported vaccination data were in excellent
agreement with those obtained from patients’ electronic ﬁles
(kappa statistic of 0.87, p <0.001) [16], indicating good validity
of the data sources. According to the Israel Centre for Disease
Control data, vaccination rates in Israel in the studied winter
were 15.7% in the entire population and 57.2% in persons
>65 years of age.
Predictive factors found to be independently associated
with vaccination on multivariable analysis were younger age,
country of birth (non-Russian origin), past pneumococcal and
inﬂuenza vaccinations, H1N1 vaccine in 2009–2010, and
low-risk malignancy. Although these factors cannot be
changed, they can be used to identify patients at high risk for
non-compliance with vaccination, and increased awareness will
allow interventions targeting these groups. The strongest
association was observed with previous inﬂuenza vaccination.
Non-compliance with inﬂuenza vaccination in the past can be
easily identiﬁed, and these patients should be targeted for
increased efforts to promote vaccination. In the multivariable
model for interviewed patients, the most prominent factors
associated with vaccination were physicians’ recommenda-
tions: the oncologist’s recommendation was associated with
vaccination with an OR of 10.7 (p <0.001), and the
primary-care physician’s recommendation was associated with
vaccination with an OR of 3.35 (p < 0.001). Regrettably, of 561
interviewees, only 113 (20.1%) remembered that their oncol-
ogist recommended inﬂuenza vaccination, and the majority
(87.6%) of these were vaccinated. An explanation about
vaccine safety also seems to be important, as 23.5% of
unvaccinated interviewees gave fear of adverse effects as the
reason for not being vaccinated.
Vaccination rates (46%) were slightly higher in our cohort of
a mixed adult cancer population in 2010 than previously
reported. Rates of inﬂuenza vaccination were 33% among
patients receiving chemotherapy in London in 2002 [17], 30%
among patients with solid cancers, 73% of whom had
TABLE 2. Oncological disease characteristics
Variable
Vaccinated
(N = 387) (%)
Unvaccinated
(N = 419) (%) p
Cancer typea
Breast 84 (21.7) 126 (30.1) 0.001
Colon 64 (16.5) 68 (16.2)
Lung 27 (7) 33 (7.9)
Other solid
malignancies
98 (25.3) 116 (27.7)
Haematological 114 (29.5) 76 (18.1)
Months since diagnosis No.
evaluated = 380
No.
evaluated = 418
<0.001
<6 130 (34.2) 197 (47.1)
≥6 257 (65.8) 22 (52.9)
Radiation therapy 172 (44.4) 218 (52) <0.001
Steroid treatmentb 103 (26.6) 131 (31.3) 0.146
Active chemotherapy in
winter 2010c
264 (68.2) 273 (65.2) 0.357
High-risk malignancyd 186 (44.4) 233 (55.6) 0.032
Neutropenia during
wintere
47 (12.1) 49 (11.7) 0.844
Severe neutropenia
during wintere
25 (6.5) 20 (4.8) 0.297
Lymphopenia during
wintere
207 (53.5) 245 (58.5) 0.154
Severe lymphopenia
during wintere
95 (24.5) 122 (29.1) 0.144
aDeﬁned as the active cancer, as some patients had other types of cancer in the
past.
bDeﬁned as 20 mg of prednisone-equivalent daily for ≥14 days.
cDeﬁned as chemotherapy given between November 2010 and February 2011.
dHigh-risk malignancy included metastatic solid tumours, leukaemia including
myelodysplastic syndromes, and HSCT. Low-risk malignancy included non-meta-
static solid cancer, lymphoma, and multiple myeloma without HSCT.
eCytopenias were deﬁned as at least one measurement below the cut-off:
neutropenia, <500 cells/lL; severe neutropenia, <100 cells/lL; lymphopenia,
<900 cells/lL; and severe lymphopenia, <400 cells/lL. Also on comparison of
the total number of days with documented cytopenia, there were no signiﬁcant
differences between groups in any of the blood counts.
TABLE 3. Questionnaire data: healthcare provider recom-
mendations and triggers for vaccination decision
Variable
Vaccinated
(N = 293) (%)
Unvaccinated
(N = 268) (%) p
Recommendation by
oncologist
No.
evaluated = 293
No.
evaluated = 267
<0.001
Not to receive 1 (0.3) 15 (5.6)
To receive 99 (33.8) 14 (5.2)
No recommendation 191 (65.2) 235 (88)
Don’t remember 2 (0.7) 3 (1.1)
Recommendation by
primary-care physician
No.
evaluated = 293
No.
evaluated = 267
<0.001
Not to receive 0 12 (4.5)
To receive 136 (46.4) 66 (24.7)
No recommendation 155 (52.9) 186 (69.7)
Don’t remember 2 (0.7) 3 (1.1)
Recommendation by other No.
evaluated = 293
No.
evaluated = 267
0.046
Not to receive 0 3 (1.1)
To receive 24 (8.2) 32 (12)
No recommendation 269 (91.8) 230 (86.1)
Don’t remember 0 2 (0.7)
Trigger for decision
Primary disease 90 (30.7) 66 (24.6) 0.108
Regular habit 87 (29.7) 58 (21.6) 0.03
Accessibility 4 (1.4) 7 (2.6) 0.29
Healthcare provider
recommendation
90 (30.7) 54 (20.15)a <0.001
aOf these, 22 (8.2%) received a recommendation not to vaccinate and 32 (11.9%)
received no recommendation.
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metastases, in Paris in 2008 [18], and 43% among colorectal
cancer patients in the USA in 1998 [12]. The association
between physicians’ recommendations and vaccine uptake
among cancer patients has not been previously reported, to
our knowledge, although the importance of this factor was
stressed in a French study reporting that 72% of unvaccinated
cancer patients claimed that lack of a recommendation by the
treating physician was the main reason for their decision [18],
and in a study in the USA, in which only 7% of patients
reported having received a recommendation for inﬂuenza
vaccination from their oncologist [19]. Also in the general
population, lack of recommendations was identiﬁed as a
barrier to adult immunization against inﬂuenza [20]. In the
general population, it has been recognized that previous
vaccination leads to continued vaccination. It is interesting
that this remains true after cancer diagnosis, as shown in our
study [21,22]. As in our study, studies in the general
population have not found an association between inﬂuenza
vaccination and education level [19,23,24]. We focused on
Russian immigrants, as lower vaccination rates have been
previously shown among Israeli patients born in Russia
[25,26] and among Russian immigrants in the USA [27]. As
there was no association between Russian origin and
socio-economic status (data not shown), we believe that
the association between Russian origin and vaccination reﬂect
cultural beliefs and habits.
Our study has several limitations. Data dealing with patient
views and triggers for vaccination were obtained from a
subgroup of responders who were interviewed. This subgroup
probably consisted of ‘less ill’ patients (better performance
status and better prognosis) who were alive at the end of the
inﬂuenza season and accessible (Fig. 1). Data on recommen-
dations relied on patients’ reports. Patients might have
reported their interpretations or perceptions regarding phy-
sicians’ recommendations rather than the actual recommen-
dations, which could bias the results in favour of an association
between the perceived recommendation and vaccination
status. A recall bias might have inﬂuenced the patients’
reported triggers to vaccinate. Another limitation is that the
study was conducted in a single teaching hospital and included
patients from a speciﬁc HMO, which might limit the general-
izability of the results. However, the hospital belongs to the
largest HMO in Israel, which insures 52.3% of its population
[14].
In summary, we identiﬁed several non-modiﬁable factors
and a single modiﬁable factor (physicians’ recommendations)
that were associated with inﬂuenza vaccination among cancer
patients. The most prominent ﬁndings are the tendency of
‘habitual vaccinees’ to continue inﬂuenza vaccination when ill
with cancer, and the major inﬂuence of physicians’ recom-
mendations, especially those of the oncologist, on patients’
behaviour. The ﬁrst factor can be easily used to target
interventions promoting inﬂuenza vaccination, and the second
factor should be improved, as rates of perceived clinicians’
recommendations were low in our study, as in previous
studies. The strong association between vaccination and the
oncologist’s recommendation highlights the faith and conﬁ-
dence of the patient in their treating oncologists. Inﬂuenza
vaccine might offer, to some degree, protection in immuno-
compromised patients [7], was associated with lower all-cause
TABLE 4. Signiﬁcant factors in the multivariable regression model for vaccination.
All patients (N = 806, included in model
N = 798)a
Interviewed patients (N = 561, included in model
N = 515)b
p OR
95% CI for OR
p OR
95% CI for OR
Lower Upper Lower Upper
Variable
Agec NS 0.020 0.98 0.96 0.996
Born in Russia 0.040 0.58 0.34 0.98 NS
Inﬂuenza vaccine last year 0.014 1.84 1.13 2.99 NS
No. of inﬂuenza vaccines in the past 5 yearsd 0.000 1.47 1.28 1.68 .000 1.74 1.49 2.03
H1N1 vaccine 2009–2010 0.016 1.82 1.12 2.95 .015 2.25 1.17 4.32
Past pneumococcal vaccine 0.000 2.27 1.58 3.26 .000 3.02 1.79 5.09
High-risk malignancy 0.005 0.61 0.43 0.86
Recommendation by oncologist NA 0.000 10.70 5.40 21.23
Recommendation by primary-care physician NA 0.000 3.35 2.05 5.49
Test performance
Hosmer and Lemeshow test 0.39 v2 = 8.45 0.381 v2 = 8.56
–2 log-likelihood <0.001 v2 = 276.36, d.f. = 6 <0.001 v2 = 251.3, d.f. = 6
Area under the ROC curve <0.001 AUC = 0.82 0.79 0.85 <0.001 AUC = 0.88 0.85 0.91
d.f., degrees of freedom; NA, not assessed; NS, non-signiﬁcant; ROC, receiver operating characteristic.
aVariables available in the regression that were not statistically signiﬁcant and not included in the ﬁnal model were: age, marital status, diabetes, inﬂuenza vaccine in the past
10 years, type of cancer, radiation therapy, and time since diagnosis of cancer.
bVariables available in the regression that were not statistically signiﬁcant and not included in the ﬁnal model were: country of birth, inﬂuenza vaccine in the past 10 years, inﬂuenza
vaccine in the previous year, type of cancer, house crowding, and recommendation from sources other than the oncologist/primary-care physician.
cOR per 1 year.
dOR per one vaccine.
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mortality in the current cohort [13], and has no potential to
cause inﬂuenza; thus, we believe that all cancer patients should
be vaccinated. Future studies should focus on characterizing
the ‘patients who vaccinate out of habit’, and explore ways to
encourage and inculcate a standard of inﬂuenza vaccine
recommendation by physicians.
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